Osivax – a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating respiratory viruses – announced the first closing of its Series B financing, raising €10 million from new and existing investors.
The company also welcomes Meiji Seika Pharma Co., Ltd, a leading Japanese pharmaceutical company specializing in infectious diseases, as a new investor. With a legacy over 75 years, Meiji Seika Pharma is a subsidiary of the Meiji Group and brings extensive expertise in vaccine development and commercialization.
The funding secured from Meiji Seika Pharma, new and existing investors, combined with non-diluted funding, will support the continued preclinical and clinical development of OVX836, Osivax’s broad-spectrum influenza vaccine candidate. This includes a Phase 2b field efficacy study (NCT05569239), designed for evaluating OVX836 against placebo in a large cohort of 2,850 participants across multiple international sites. The study represents a significant step in advancing the science of influenza prevention beyond conventional approaches.
KEY QUOTE:
“This funding is a strong endorsement of our technology, our team and our vision to develop broad-spectrum influenza vaccine candidates. We are gaining significant momentum in advancing Osivax’s development strategy, and we are thrilled to welcome Meiji Seika Pharma as a new investor. Their support, alongside that of our existing investors, reinforces our shared ambition to transform the prevention of respiratory infectious diseases.”
– Alexandre Le Vert, CEO and Co-Founder of Osivax
